BlueSphere Bio to Present at the Next Generation CAR & T Cell Therapies Conference
March 01, 2023 10:17 ET
|
BlueSphere Bio
PITTSBURGH, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio to Present at the 25th Annual BIO CEO & Investor Conference
February 06, 2023 10:17 ET
|
BlueSphere Bio
PITTSBURGH, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio Appoints Erkut Bahceci, M.D., as Chief Medical Officer
January 30, 2023 10:17 ET
|
BlueSphere Bio
Dr. Bahceci brings more than two decades of combined clinical and drug development experience PITTSBURGH, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell...
BlueSphere Bio Presents Data Demonstrating the Potential of Lead Product Candidate at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2022 09:00 ET
|
BlueSphere Bio
BSB-1001 is the first product candidate from the TCX-101 platformData supports BSB-1001 as a potential treatment to improve outcomes for patients with acute myeloid leukemia (AML) receiving a...
BlueSphere Bio Data to be Presented at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 03, 2022 10:17 ET
|
BlueSphere Bio
PITTSBURGH, Nov. 03, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer
October 04, 2022 10:17 ET
|
BlueSphere Bio
PITTSBURGH, Oct. 04, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at 7th Annual CAR-TCR Summit
September 26, 2022 09:45 ET
|
BlueSphere Bio
PITTSBURGH, Sept. 26, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio to Present at the 7th Annual CAR-TCR Summit
September 19, 2022 10:30 ET
|
BlueSphere Bio
PITTSBURGH, Sept. 19, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio to Present a Corporate Overview at the 2022 BIO International Convention
June 13, 2022 11:40 ET
|
BlueSphere Bio
PITTSBURGH, June 13, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio Data to be Presented at the 2022 Joint ASTCT + EBMT Basic and Translational Scientific Retreat
May 25, 2022 10:17 ET
|
BlueSphere Bio
PITTSBURGH, May 25, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients...